Professor, Internal Medicine, UC, Davis School of Medicine
Hematology
Dr. David R. Gandara, MD
|
|
Give Review
Dr. David R. Gandara practices Hematology. He received 6 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Fellow (FASCO)", "Super Doctor" and "Whos Who in Medicine and Healthcare". David Gandara has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast...' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Perfo...
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer.
- Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B Analog) during a phase I trial in patients with advanced solid tumors: a California ...
- Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWO...
- Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
- Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.
- Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid Tumors.
- P1.06Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid Tumors.
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung Cancer (CheckMate 063):...
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced Malignant pleural mesothelioma (MPM).
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Local...
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
- Phase I study of the halichondrin B Analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
- Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncolog...
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung...
- Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung Cancer cell lines.
- Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Can...
- Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220.
- Predictors of survival for younger patients less than 50 years of age with non-small cell lung Cancer (NSCLC): A California Cancer Registry analysis.
- Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung Cancer.
- Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non-Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Tran...
- KRAS mutations in non-small-cell lung Cancer and colorectal Cancer: Implications for EGFR-targeted therapies.
- Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0...
- Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications.
- Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy.
- FASTACT-2: but don't act too fast.
- A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid Tumors.
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012.
- Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
- Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput Analyses.
- Non-Small-Cell Lung Cancer: Then and Now.
- Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced AdenoCarcinoma.
- Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies.
- The CD22 Antigen is Broadly Expressed on Lung Cancer Cells and is a Target for Antibody-based Therapy.
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819.
- Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity.
- Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma.
- A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic Cancer.
- Aberrant Regulation of the MRP3 Gene in Non-small Cell Lung Carcinoma.
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California...
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.
- Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial.
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin.
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell Carcinoma: combined mTOR and AKT inhibitor therapy.
- Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer.
- Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
- A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell Carcinoma.
- Biomarkers of DNA repair and related pathways: significance in non-small cell lung Cancer.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung Cancer: a California Cancer consortium trial.
- Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung Cancer: final pati...
- Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung Cancer.
- Sorafenib in platinum-treated patients with extensive stage small cell lung Cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
- Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung Cancer: Southw...
- Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung Cancer.
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
- The tissue is the issue: personalized medicine for non-small cell lung Cancer.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung Cancer (National Ca...
- Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study.
- Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung Cancer: NCCTG and SWOG study N0426.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung Cancer.
- Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
- Evolving treatment algorithms for advanced non-small-cell lung Cancer: 2009 looking toward 2012.
- Cooperative group research endeavors in small-cell lung Cancer: current and future directions.
- Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung Cancer: a model for assessing population-related pharmacogenomics.
- A decade of clinical lung Cancer.
- Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
- Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung Cancer: SWOG 0222.
- Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung Cancer: clinical and pharmacogenomic results from SWOG S0124.
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast Cancer.
- Individualizing therapy for non-small-cell lung Cancer: a paradigm shift from empiric to integrated decision-making.
- The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung Cancer cells.
- Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung Cancer: exploring a new frontier.
- Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung Cancer.
- Oral fenretinide in biochemically recurrent prostate Cancer: a California Cancer consortium phase II trial.
- A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast Cancer: a California Cancer Consortium study.
- Cooperative group research efforts in lung Cancer 2008: focus on advanced-stage non-small-cell lung Cancer.
- Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung Cancer patients receiving platinum-based chemotherapy: SWOG Study...
- Progress in small-cell lung Cancer: the lowest common denominator.
- A multigene assay is prognostic of survival in patients with early-stage lung adenoCarcinoma.
- Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung Cancer and a performance status of 2.
- Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular Cancer: a California Cancer Consortium Trial.
- Positron emission tomography and improved survival in patients with lung Cancer: the Will Rogers phenomenon revisited.
- Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung Cancer patients treated with cetuximab and chemot...
- First-generation epidermal growth factor receptor inhibitors in non-small cell lung Cancer: clinical impact of the epidermal growth factor receptor fluorescence in sit...
- Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung Cancer: ...
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
- Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
- Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in Cancer.
- Aurora kinases as antiCancer drug targets.
- Cooperative group portfolio in locally advanced non-small-cell lung Cancer: are we making progress?
- Cooperative group research efforts in lung Cancer: focus on early-stage non-small-cell lung Cancer.
- Overcoming barriers to Cancer clinical trial accrual: impact of a mass media campaign.
- Targeted therapies in non-small-cell lung Cancer: a paradigm in evolution.
- Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative Breast...
Schools
University Of Texas Medical Branch At Galveston
Madigan Med Center
Letterman Army Med Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Guided Access HMO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Delta Health System
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Humana
- Medicare MCR
- MultiPlan PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Western Health Advantage
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Fellow (FASCO)
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
Madigan Healthcare System -
University of Texas Medical Branch
Hospital
-
University of California, Davis Medical Center
Drug Facts
| NPI NUMBER | 1528042587 | |
| NPPES Provider LastName | GANDARA | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 958172229 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528042587 |
| Last Name Of The Provider | GANDARA |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Minh T. Huynh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denis M. Dwyre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanna L. Welborn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lai Hui, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kit S. Lam, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ted Wun, MD |
|
|
Dr. Ryan F. Kendle, MD |